戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 opamine receptor agonist) and haloperidol (a dopamine receptor antagonist).
2 ncreases were not inhibited by a D1 subclass dopamine receptor antagonist.
3 mate receptor antagonist, or SCH 23390, a D1 dopamine receptor antagonist.
4 oselective synthesis of (+)-sonepiprazole, a dopamine receptor antagonist.
5 ion and depression-like symptoms, than other dopamine receptor antagonists.
6 nge alcohol drinking, and its sensitivity to dopamine receptor antagonists.
7 SCH 23390) or D2-like (100 microM sulpiride) dopamine receptor antagonists.
8 domisation was stratified by baseline use of dopamine receptor antagonists.
9 dopamine neuron stimulation and resistant to dopamine receptor antagonists.
10 ice, with exaggerated additional response to dopamine receptor antagonists.
11 cy of self-administered stimulants, and also dopamine receptor antagonists.
12 phrenia have in common the property of being dopamine-receptor antagonists.
13                   By administering the D2/D3 dopamine receptor antagonist [(11)C]raclopride at varyin
14 size DHCB and show that it displays moderate dopamine receptor antagonist activities.
15 ent to which bilateral aDLS infusions of the dopamine receptor antagonist alpha-flupenthixol (0, 5, 1
16 infusion into the anterior DLS (aDLS) of the dopamine receptor antagonist alpha-flupentixol.
17                                              Dopamine receptor antagonists also showed high affinity,
18  the effect of co-administering SCH23390 (D1 dopamine receptor antagonist) and quinpirole (D2 dopamin
19                   SCH23390, a selective D(1) dopamine receptor antagonist, and (-)-butaclamol did not
20 creening we identify two drugs, L-745,870, a dopamine receptor antagonist, and aminocaproic acid, a p
21                                  A number of dopamine receptor antagonist/antipsychotic agents were s
22 bute to the pathophysiology of migraine, and dopamine receptor antagonists are prescribed in the trea
23                                        Novel dopamine receptor antagonists aripiprazole and ecopipam
24                        Although a variety of dopamine receptor antagonists blocked cocaine self-admin
25            The binding of the fluorescent D1 dopamine receptor antagonist bodipy-SCH 23390 was measur
26 l history of tardive dystonia resulting from dopamine-receptor antagonist (DRA) treatment in 107 pati
27 skinesia (TD) can occur in people exposed to dopamine receptor antagonists (DRAs).
28 d was abolished by administration of a D1/D5 dopamine receptor antagonist during the exposure session
29 Prolixin(R)) is a potent phenothiazine-based dopamine receptor antagonist, first introduced into clin
30 ion, was attenuated by pretreatment with the dopamine receptor antagonist, flupenthixol, into the cor
31            Both cis and trans isomers of the dopamine receptor antagonist flupentixol inhibit drug tr
32 f systemic administration of the nonspecific dopamine receptor antagonist flupentixol on response inv
33 intra-accumbens microinjection of either the dopamine receptor antagonist flupentixol or the nicotini
34 n determined; in addition, the effect of the dopamine receptor antagonist fluphenazine (0.1-1.0 mg/kg
35       Consistent with this notion, the D1/D2 dopamine receptor antagonist fluphenazine blocked footsh
36 induced rotational behavior was blocked by a dopamine receptor antagonist (fluphenazine).
37       Treatment of aged mutant mice with the dopamine receptor antagonist haloperidol precipitated mo
38                         Pre-treatment with a dopamine receptor antagonist (haloperidol, 0.25 mg/kg; i
39                          DISC was blocked by dopamine receptor antagonists (haloperidol, clozapine, e
40            After 7-day administration of the dopamine receptor antagonist, haloperidol (1 mg/kg), no
41 scimol was attenuated by administration of a dopamine receptor antagonist, haloperidol.
42 the increase in dopamine turnover and by the dopamine receptor antagonists, haloperidol, clozapine, a
43 iously, systemic administration of selective dopamine receptor antagonists has been shown to reduce a
44                    Domperidone, a peripheral dopamine receptor antagonist, has been successfully used
45 ipsychotic potential of a highly specific D4 dopamine receptor antagonist (ie, L-745,870) in patients
46                       Previous studies using dopamine receptor antagonists implicate the involvement
47                                  The role of dopamine receptor antagonists in the photoreceptor funct
48  ng/ml PTX or with 1 microM L745,870, a D(4) dopamine receptor antagonist, indicating that activation
49 neous recording of neuronal firing and local dopamine receptor antagonist injection.
50 the nucleus accumbens core and infusion of a dopamine receptor antagonist into the contralateral dors
51 perant tasks and determined how injection of dopamine receptor antagonists into the accumbens influen
52    Like VTA baclofen injection, injection of dopamine receptor antagonists into the NAc profoundly re
53                             The selective D4 dopamine receptor antagonist L-745,870 was ineffective a
54                           This action of the dopamine receptor antagonists may contribute to their an
55 y D2 receptor blockade determines whether D2 dopamine receptor antagonist-mediated gene expression is
56 ors, hopes have run high that a selective D4 dopamine receptor antagonist might improve the pharmacol
57 -accumbens core flupenthixol, a nonselective dopamine receptor antagonist, on context renewal.
58 yperactivity was abolished by treatment with dopamine receptor antagonists or catecholamine biosynthe
59                                              Dopamine receptor antagonists or dopamine depletion fail
60 en injected systemically with flupentixol, a dopamine receptor antagonist, or vehicle before testing
61 nit activity was unaffected by D1 or D2-like dopamine-receptor antagonists, or by inhibition of evoke
62 ay system to measure the pharmacokinetics of dopamine receptor antagonists, presumably in the brain,
63 s prolonged by perfusion of the selective D2 dopamine receptor antagonist raclopride (100 microM) int
64 ated ARS behavior, as did application of the dopamine receptor antagonist raclopride.
65 pical antipsychotic drug that is primarily a dopamine receptor antagonist, reduced 5-HT2C VNV isoform
66             Treatment with haloperidol, a D2 dopamine receptor antagonist, reduces this abnormal intr
67 ion of haloperidol (0.5 or 1.0 mg/kg, sc), a dopamine receptor antagonist, reversed both the behavior
68 bilateral intracranial injections of the D-1 dopamine receptor antagonist SCH 23390 HCl (0, 0.8, 1.6,
69 luence of bilateral VTA injections of the D1 dopamine receptor antagonist SCH 23390 or the 5-HT2 rece
70             In contrast, perfusion of the D1 dopamine receptor antagonist SCH-23390 (100 microM) did
71 hold was significantly increased by the D(1) dopamine receptor antagonist SCH23390 (10 microg kg(-1),
72 d persistent activity was enhanced by the D1 dopamine receptor antagonist SCH23390 [R(+)-7-chloro-8-h
73                                       The D1 dopamine receptor antagonist SCH23390, and the recombina
74  t-LTP was completely blocked by the D1-like dopamine receptor antagonist SCH23390, but not by the D2
75 e, although, for a minority of units, the D1 dopamine-receptor antagonist SCH23390 attenuated neural
76 ed" methamphetamine seeking, using selective dopamine receptor antagonists (SCH39166 or raclopride) a
77 reatment of cells with 10 muM SCH23390, a D1 dopamine receptor antagonist, significantly inhibited th
78 electrophysiological action of droperidol, a dopamine receptor antagonist, since these cultures conta
79                                        Other dopamine receptor antagonists, spiperone and clozapine,
80  Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypi
81  and can be blocked in rats and monkeys with dopamine receptor antagonists, suggesting that increased
82 dopamine receptor agonist bromocriptine or a dopamine receptor antagonist sulpiride (dopamine study n
83  we investigate how a high dose of the D2/D3 dopamine receptor antagonist sulpiride impacts learning
84  antagonist SCH23390, but not by the D2-like dopamine receptor antagonist sulpiride.
85 ts, whereas administration of D1- or D2-like dopamine receptor antagonists to further reduce dopamine
86  by measuring the ability of sulpiride, a D2 dopamine receptor antagonist, to increase the depolariza
87                             Thus, infusing a dopamine receptor antagonist unilaterally into the basol
88 ed reinstatement by all compounds, whereas a dopamine receptor antagonist was effective only in block
89                                  A number of dopamine receptor antagonists were inverse agonists at D
90 dyskinetic clozapine (1) is a low-potency D2 dopamine receptor antagonist which appears to act select
91 se in the striatum, and haloperidol (hal), a dopamine receptor antagonist with high affinity for D2-l
92 r findings suggest that the combination of a dopamine receptor antagonist with radiation enhances the